Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Alemtuzumab in Relapsed/Refractory B-CLL
NCT00328198Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2006
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Sanofi. Started May 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00328198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00328198.